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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
Lactobacillus paracasei LPC 01 (CNCM I-1390) and treatment of disease 
(ID 3055, further assessment) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on a health claim pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment related to Lactobacillus paracasei LPC 01 (CNCM I-1390) 
and treatment of disease. The food constituent, L. paracasei LPC 01 (CNCM I-1390), is sufficiently 
characterised. The claimed effect proposed for further assessment is “relieve symptoms typically associated with 
Irritable Bowel Syndrome (IBS), especially diarrhoea-predominant IBS, and to help reduce the daily number of 
bowel movements as well as improve the consistency of faeces in adult subjects reporting acute diarrhoea”. The 
proposed target population is “adults suffering either from Irritable Bowel Syndrome, especially 
diarrhoea-predominant IBS, or from acute diarrhoea”. The Panel considers that the claimed effect is related to the 
treatment of a disease and does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to 
Article 13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States 
that a certain number of Article 13 health claims would be eligible for further assessment by EFSA in 
order to be able to take a final decision on whether or not to include these claims in the list of 
permitted health claims. This opinion addresses the scientific substantiation of health claims in 
relation to Lactobacillus paracasei LPC 01 (CNCM I-1390) and treatment of disease. The scientific 
substantiation is based on the information provided by the competent Authority of Italy for further 
assessment of this claim. 
The food constituent that is the subject of the health claim is L. paracasei LPC 01 (CNCM I-1390). 
The Panel considers that L. paracasei LPC 01 (CNCM I-1390) is sufficiently characterised. 
The claimed effect, which is proposed for further assessment, is “relieve symptoms typically 
associated with Irritable Bowel Syndrome (IBS), especially diarrhoea-predominant IBS, and to help 
reduce the daily number of bowel movements as well as improve the consistency of faeces in adult 
subjects reporting acute diarrhoea”. The proposed target population is “adults suffering either from 
Irritable Bowel Syndrome, especially diarrhoea-predominant IBS, or from acute diarrhoea”.  
The Panel considers that the claimed effect is related to the treatment of a disease and does not 
comply with the criteria laid down in Regulation (EC) No 1924/2006. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect.  
Following an opinion of the NDA Panel on a health claim pursuant to Article 13 of Regulation (EC) 
No 1924/2006
4
 in which the Panel concluded that the data available were not sufficient to characterise 
Lactobacillus paracasei LPC 01 (CNCM I-1390) (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2010), EFSA received additional information from the competent Authority of Italy 
for further assessment of this claim. The information provided in the framework of further assessment 
for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
5
.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:   
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (“beneficial to human health”);   
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately, 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Characterisation of the food/constituent (ID 3055) 
The food constituent that is the subject of the health claim is Lactobacillus paracasei LPC 01 (CNCM 
I-1390). 
A culture collection number from the Collection Nationale de Cultures de Microorganismes 
(CNCM I-1390) was provided. The CNCM is a restricted-access non-public collection which has the 
status of an International Depositary Authority under the Budapest Treaty. Data on the identification 
and characterisation of L. paracasei LPC 01 at species and strain level, by using both phenotypic 
(carbohydrate fermentation pattern, enzymatic activity profile, PAGE, antibiotic resistance profile) 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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and genotypic (ARDRA, species-specific PCR, plasmidic profile, PFGE, genome sequencing) 
methods, were provided in the application for further assessment and accompanying annexes, and in 
the references provided (Elli M. et al., 2009; Morelli et al., 2003; 2006). L. paracasei LPC 01 is also 
known as L. paracasei B21060.  
The Panel considers that the food constituent, L. paracasei LPC 01, which is the subject of the health 
claim, is sufficiently characterised.  
2. Relevance of the claimed effect to human health (ID 3055)  
The claimed effect, which is proposed for further assessment, is “relieve symptoms typically 
associated with Irritable Bowel Syndrome (IBS), especially diarrhoea-predominant IBS, and to help 
reduce the daily number of bowel movements as well as improve the consistency of faeces in adult 
subjects reporting acute diarrhoea”. The proposed target population is “adults suffering either from 
Irritable Bowel Syndrome, especially diarrhoea-predominant IBS, or from acute diarrhoea”.  
The Panel considers that the claimed effect is related to the treatment of a disease and does not 
comply with the criteria laid down in Regulation (EC) No 1924/2006. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, L. paracasei LPC 01, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect proposed for further assessment is “relieve symptoms typically associated 
with Irritable Bowel Syndrome (IBS), especially diarrhoea-predominant IBS, and to help 
reduce the daily number of bowel movements as well as improve the consistency of faeces in 
adult subjects reporting acute diarrhoea”. The proposed target population is “adults suffering 
either from Irritable Bowel Syndrome, especially diarrhoea-predominant IBS, or from acute 
diarrhoea”.  
 The claimed effect is related to the treatment of a disease and does not comply with the 
criteria laid down in Regulation (EC) No 1924/2006.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment 
(No: EFSA-Q-2012-00208). The scientific substantiation is based on the information provided by the 
competent Authority of Italy for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
REFERENCES  
EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010. Scientific Opinion on the 
substantiation of health claims related to non characterised bacteria and yeasts pursuant to Article 
13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 8(2):1470, 44 pp. 
Elli M, Grossi E and Morelli L, 2009. Lessons from probiotics genome sequence: the example of L. 
paracasei B 20160. 5th Probiotics and Prebiotics and New Foods, 13-15 September. 
L. paracasei LPC 01 (CNCM I-1390) and treatment of disease (further assessment) 
 
7 EFSA Journal 2012;10(8):2850 
Morelli L, Zonenschain D, Callegari ML, Grossi E, Maisano F and Fusillo M, 2003. Assessment of a 
new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its 
effect on the indigenous flora. Nutrition Journal, 2, 11. 
Morelli L, Garbagna N, Rizzello F, Zonenschain D and Grossi E, 2006. In vivo association to human 
colon of Lactobacillus paracasei B21060: map from biopsies. Digestive and Liver Disease, 38, 
894-898. 
 
 
L. paracasei LPC 01 (CNCM I-1390) and treatment of disease (further assessment) 
 
8 EFSA Journal 2012;10(8):2850 
APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6  OJ L12, 18/01/2007 
7  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
L. paracasei LPC 01 (CNCM I-1390) and treatment of disease (further assessment) 
 
10 EFSA Journal 2012;10(8):2850 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Health claims related to Lactobacillus paracasei LPC 01 (CNCM I-1390), including 
conditions of use, as proposed in the framework of further assessment. 
ID Food or Food constituent Health Relationship Proposed wording 
3055 Lactobacillus paracasei 
LPC 01 (CNCM I-1390) 
relieve symptoms typically 
associated with Irritable Bowel 
Syndrome (IBS), especially 
diarrhea-predominant IBS, and 
to help reduce the daily number 
of bowel movements as well as 
improve the consistency of 
faeces in adult subjects reporting 
acute diarrhea  
Contributes to reduce 
intestinal discomfort and other 
symptoms typically associated 
with Irritable Bowel 
Syndrome, especially in case 
of diarrhea-predominant IBS, 
also shortening the duration of 
acute diarrhea and restoring a 
physiological intestinal transit. 
Conditions of use 
The target population is represented by adults suffering either from Irritable Bowel Syndrome, 
especially diarrhea-predominant IBS, or from acute diarrhea. Therefore, a moderate to significant 
impairment of intestinal motility and consistency of faeces is common to both conditions.  
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GLOSSARY AND ABBREVIATIONS 
ARDRA Amplified rDNA restriction analysis 
CNCM  Collection Nationale de Cultures de Microorganismes, France 
DNA Deoxyribonucleic acid 
IBS  Irritable bowel syndrome 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase chain reaction 
PFGE  Pulsed field gel electrophoresis 
